In this issue of Blood, Stein et al1 demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al2 investigate mechanisms of response in samples derived from the same patients.

Additional Metadata
Persistent URL,
Journal Blood
Wouters, B.J. (2017). Hitting the target in IDH2 mutant AML. Blood (Vol. 130, pp. 693–694). doi:10.1182/blood-2017-06-790394